​MCT8 deficiency had no approved US treatment until now

Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome (AHDS), is a rare X-linked disorder characterized by two simultaneous and opposing thyroid hormone crises in the same person. With fewer than 600 known patients worldwide and a reported median life expectancy of approximately 35 years, this condition had no approved pharmacological treatment in the United States until September 28, 2026.

The disorder arises from pathogenic mutations in SLC16A2, the gene encoding MCT8, a cell-surface transporter responsible for ferrying thyroid hormones across the plasma membrane and blood-brain barrier (BBB). When MCT8 is absent or dysfunctional, the biologically active thyroid hormone triiodothyronine (T3) cannot reach the developing brain, causing severe cerebral hypothyroidism marked by profound intellectual disability, hypotonia, absent or minimal motor development, and dystonia. Simultaneously, T3 accumulates to toxic levels in peripheral tissues, producing chronic thyrotoxicosis that strains the heart, muscles, liver, and kidneys.

Egetis Therapeutics announced that the US Food and Drug Administration (FDA) approved Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency. The approval makes Emcitate the first FDA-authorized treatment option for this population and follows the February 2025 authorization by the European Commission, where tiratricol had already become the first approved therapy for MCT8 deficiency in the European Union (EU).

Tiratricol bypasses a broken transporter

Tiratricol (triiodothyroacetic acid, also known as TRIAC) works by routing around the molecular defect that makes conventional thyroid hormone therapy ineffective in MCT8 deficiency. Standard hormone replacement — whether with T3 or thyroxine (T4) — cannot correct cerebral hypothyroidism in this population because both T3 and T4 rely on MCT8 to cross the BBB and enter neurons. Administering them without a functional transporter worsens peripheral thyrotoxicosis without reaching the brain. Tiratricol resolves this by using a different entry mechanism entirely.

Tiratricol is an endogenous metabolite of T3, is present in healthy individuals at trace concentrations, and a thyroid hormone receptor agonist. Unlike T3 and T4, tiratricol enters cells independently of the MCT8 transporter, bypassing the pathophysiological defect entirely. Once inside target cells, tiratricol activates thyroid hormone receptors in a manner similar to T3, suppressing the hypothalamic-pituitary-thyroid axis and thereby reducing circulating T3 concentrations.

By lowering the T3 burden on MCT8-independent peripheral tissues, the drug addresses the thyrotoxic component of the disease. This provides a meaningful clinical benefit even without restoring thyroid hormone to the MCT8-dependent brain, a limitation that preclinical and clinical MCT8 research recognizes as a fundamental constraint of the current treatment paradigm.

The FDA approval was supported by six studies spanning Phase 2 trials, a Phase 3 placebo-controlled withdrawal trial, real-world cohort data, and a US Expanded Access Program. The evidence base rests on tiratricol's consistent ability to normalize serum T3 concentrations and improve the clinical manifestations of chronic thyrotoxicosis. Both the FDA and the European Medicines Agency (EMA) agreed that these measurable endpoints were the appropriate regulatory basis for a disease of this severity and rarity.

What the clinical program demonstrated

Triac Trial I (NCT02060474), a Phase 2 open-label international trial, served as the primary foundation for the new drug application (NDA). Published in The Lancet Diabetes & Endocrinology, the trial showed that tiratricol reduced mean serum T3 concentrations by more than 63 percent at month 12, with every participant improving in at least one of three endpoints — body weight, resting heart rate, or systolic blood pressure — and no drug-related serious adverse events reported. An Erasmus Medical Center retrospective cohort study covering 67 patients across 33 sites and up to six years of treatment confirmed that these benefits were sustained across all ages.

The pivotal randomized evidence came from ReTRIACt (NCT05579327), a Phase 3, multicenter, double-blind, placebo-controlled withdrawal trial. Because randomizing untreated patients to placebo would have been ethically untenable in a life-limiting disorder with no approved therapy, the study instead enrolled patients already stabilized on tiratricol and randomized them to continue treatment or switch to placebo for 30 days. This withdrawal design produced a statistically significant difference (p=0.034) in the rate of change in serum T3 between groups, with every participant in the placebo arm showing the expected T3 rise that reversed upon tiratricol re-initiation. Tiratricol was well-tolerated throughout: no treatment-related serious adverse events were recorded.

Key features of the Emcitate approval and clinical program:

• Approved indication: peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (AHDS)
• Mechanism: thyroid hormone receptor agonist entering cells independently of MCT8, reducing circulating T3
• Not recommended for: treatment of primary hypothyroidism
• Clinical program: Phase 2 (Triac Trial I, Triac Trial II), Phase 3 placebo-controlled withdrawal trial (ReTRIACt), Erasmus Medical Center Cohort Study, EMC Survival Study, and US Expanded Access Program
• Regulatory designations: Breakthrough Therapy Designation, Fast Track Designation, Priority Review, Rare Pediatric Disease Designation
• Most common adverse reactions (≥5 percent): diarrhea, vomiting, rash, and hyperhidrosis
• Commercial availability: expected within eight to ten weeks of approval through specialty partner PANTHERx Rare

Andrew J. Bauer, Medical Director of the Pediatric Thyroid Center at Children's Hospital of Philadelphia and Principal Investigator in the ReTRIACt and Triac Trial II studies, said the approval provides clinicians with a tool they have long lacked. "Through my experience caring for patients with MCT8 deficiency, I have seen firsthand the profound impact this complex and life-limiting disorder can have on patients and their families," Bauer said. "Early diagnosis is critical so that patients can be appropriately evaluated, connected with specialists and receive coordinated multidisciplinary care. The FDA approval of EMCITATE provides physicians in the United States with the first approved treatment option for patients."

MCT8 deficiency: why no drug existed until now

MCT8 deficiency had no approved pharmacological treatment in the United States because the patient population is extremely small and the regulatory path demanding. Before Emcitate's approval, management consisted entirely of supportive care: nutritional supplementation, physical and occupational therapy for neuromuscular dysfunction, antiepileptic medication for seizure management, and cardiology monitoring for the cardiovascular strain imposed by chronic peripheral thyrotoxicosis.

MCT8 deficiency is X-linked and affects males almost exclusively, with female carriers typically exhibiting mild or subclinical features. Its estimated prevalence among males is approximately 1 in 70,000, placing it in the ultra-rare disease category, and fewer than 600 individuals had been identified globally as of the time of approval. Diagnosis has historically been delayed because the condition's neurological symptoms begin in the first months of life but are often mistaken for cerebral palsy or nonspecific neurodevelopmental delay, and the pathognomonic thyroid function pattern — elevated T3 with low or normal T4 — is not part of routine newborn screening.

Driven by this profound unmet clinical need and the historical reliance on purely supportive measures, global health authorities provided a highly accelerated pathway for the drug's development. This urgency translated into a swift regulatory timeline spanning multiple jurisdictions.

Nicklas Westerholm, CEO of Egetis Therapeutics, said the approval marks a transition from clinical development to patient access. "Today marks a turning point for patients living with MCT8 deficiency and their caregivers, who have waited long for an approved treatment in the United States," Westerholm said. "Our immediate focus is ensuring that eligible patients can access EMCITATE as quickly as possible."

What does tiratricol address?

Tiratricol's approval is specifically for the systemic, potentially fatal accumulation of T3 outside the brain, called peripheral thyrotoxicosis. The clinical data supporting it are meaningful: T3 normalization, improved heart rate, weight stabilization, and reduced cardiovascular strain in a disease that previously offered no pharmacological recourse. The drug does not, however, address the neurological component of MCT8 deficiency.

The severe intellectual and motor disability in people with AHDS results from cerebral hypothyroidism and tiratricol does not reach the brain in concentrations sufficient to correct this central deficit. A review of patient unmet needs identifies gene therapy, alternative transporter strategies, and combinatorial approaches as emerging avenues for the neurological phenotype, though none have reached clinical approval.

The boundaries of tiratricol's benefit were further defined by Triac Trial II (NCT02396459), a Phase 2 open-label trial investigating whether early treatment in boys younger than 30 months might improve neurocognitive outcomes as measured by the Gross Motor Function Measure-88 (GMFM-88) and Bayley Scales of Infant and Toddler Development (BSID-III). The trial did not meet its co-primary endpoints on neurodevelopmental change versus historical controls, though it confirmed durable T3 suppression in all participants. Both the FDA and EMA agreed that the approval basis should rest on T3 normalization and peripheral thyrotoxicosis benefit.

Aaccess infrastructure and global expansion for Emcitate's US launch

Egetis has built a patient access infrastructure called Egetis RareLink to support the US launch, operating through a specialty distribution partnership with PANTHERx Rare, with commercial availability expected within eight to ten weeks of the September 28 approval. Tiratricol had already reached more than 230 patients in over 25 countries through managed access programs ahead of formal US approval, meaning substantial real-world clinical experience exists beyond the trial record. The FDA approval also triggered a Rare Pediatric Disease Priority Review Voucher (PRV) which Egetis indicated it expects to explore monetizing in the fourth quarter of 2026.

Tiratricol approval signals a new standard for MCT8 deficiency care

The FDA approval of tiratricol (Emcitate) establishes the first pharmacological standard of care for MCT8 deficiency in the United States, converting a purely supportive disease management approach into one anchored by a drug that consistently normalizes serum T3 and reduces peripheral thyrotoxicosis. For the approximately 1 in 70,000 males affected by this X-linked disorder, an approved therapy represents a meaningful shift in clinical expectations. Work toward earlier diagnosis and toward therapies that may one day address the cerebral hypothyroidism moves forward with this regulatory and commercial foundation.

This article is based on a press release issued by Egetis Therapeutics and was produced under Drug Discovery News' AI Editorial Guidelines.